Ronald Joseph Rodriguez

US Patent:

7582290, Sep 1, 2009

Filed:

Apr 8, 2003

Appl. No.:

10/510592

Inventors:

Ronald Rodriguez - Glenwood MD, US
Wasim Haider Chowdhury - Laurel MD, US

Assignee:

The Johns Hopkins University - Baltimore MD

International Classification:

A61K 48/00

US Classification:

424 932

Abstract:

The invention provides a packaging cell line for production of diphtheria toxin (DT) expressing, non-replicating adenovirus for use in suicide gene therapy of cancer cells, as well as production of immunotoxins. Also provided are methods for producing diphtheria toxin (DT) expressing, non-replicating adenovirus, methods for producing immunotoxins, and adenovirus and immunotoxins produced by those methods. Further provided are methods for making a cell resistant to diphtheria toxin.

US Patent:

7662795, Feb 16, 2010

Filed:

Aug 8, 2003

Appl. No.:

10/523899

Inventors:

Ronald Rodriguez - Glenwood MD, US
Ying Li - Gibson Island MD, US

Assignee:

The Johns Hopkins University - Baltimore MD

International Classification:

A61K 31/70
C12N 15/74

US Classification:

514 44, 4353201, 435 914

Abstract:

The present invention relates to compositions and methods for enhancing the oncolytic activity of replication-competent, target cell-specific adenovirus vectors by modification of the E1A gene product. The target cell-specific replication-competent adenovirus vectors comprise a chimera of an adenovirus gene essential for replication, preferably an early gene, and the Androgen receptor (or a portion thereof) under the transcriptional control of a cell type-specific transcriptional regulatory element (TRE). By providing for cell type-specific transcription through the use of one or more cell type-specific TREs, the adenovirus vectors effect prostate-specific cytotoxicity due to selective replication.

US Patent:

7749968, Jul 6, 2010

Filed:

Aug 5, 2003

Appl. No.:

10/523498

Inventors:

Ronald Rodriguez - Glenwood MD, US
Shawn E. Lupold - Ellicott City MD, US

Assignee:

The Johns Hopkins University - Baltimore MD

International Classification:

A61K 38/08

US Classification:

514 16, 514 15, 530328, 530329

Abstract:

The invention provides isolated PSMA binding peptides, as well as pharmaceutical compositions thereof. Also provided are diagnostic and therapeutic methods utilizing the PSMA binding peptides, as well as methods for identifying further PSMA binding peptides.

US Patent:

8088621, Jan 3, 2012

Filed:

Sep 14, 2007

Appl. No.:

11/901275

Inventors:

Ronald Rodriguez - Glenwood MD, US
Shawn Edward Lupold - Ellicott City MD, US
Wasim Haider Chowdhury - Laurel MD, US
Tarana A. Kudrolli - Frederick MD, US

Assignee:

The Johns Hopkins University - Baltimore MD

International Classification:

C12N 15/87

US Classification:

435462, 435465, 435466, 435475, 435477, 435488

Abstract:

The instant invention provides methods and compositions for generating recombinant adenoviral vectors. The invention also provides kits comprising for the generation of recombinant adenoviral vectors.

US Patent:

20090074658, Mar 19, 2009

Filed:

Aug 18, 2008

Appl. No.:

12/193624

Inventors:

Shawn E. Lupold - Ellicott City MD, US
Ronald Rodriguez - Glenwood MD, US
Wasim H. Chowdhury - Laurel MD, US
Tarana A. Kudrolli - Frederick MD, US

Assignee:

The Johns Hopkins University - Baltimore MD

International Classification:

A61K 49/00
C40B 30/04
C07H 21/04
C12N 15/63
C12N 1/00
C40B 40/08
A61K 51/00
C12N 5/06
C12N 1/20
C40B 50/06
C12N 15/861
C12N 7/00

US Classification:

424 111, 506 9, 536 254, 4353201, 435243, 506 17, 435325, 4352521, 506 26, 435440, 4352351, 424 96

Abstract:

The present invention provides DNA libraries, libraries of viral clones and libraries of infectious viral particles and methods of generating and screening these libraries.

US Patent:

20120308521, Dec 6, 2012

Filed:

Dec 2, 2010

Appl. No.:

13/511878

Inventors:

Ronald Rodriguez - Glenwood MD, US
Naser Uddin Hoti - Baltimore MD, US

International Classification:

A61K 48/00
C12N 5/09
A61P 35/00
C12Q 1/70
G01N 33/574
C12N 15/861
C12N 13/00

US Classification:

424 932, 4353201, 435375, 4351731, 435 5

Abstract:

The present invention includes the use of a nucleic acid sequence encoding an shRNA to target RNA interference against a cellular factor where such use can enhance oncolytic adenovius replication. The nucleic acid sequence encoding an shRNA can be introduced into an oncolytic adenovius construct via a recombination event, and such nucleic acid sequence encoding an shRNA can reside in either the E1 region or Fiber region of the oncolytic adenovius construct. In particular, the oncolytic adenovius construct optionally include a prostate specific promoter or prostate specific enhancer for issue specific expression in prostate cancer cells. The oncolytic adenovius constructs of the invention provides utility for the treatment of cancers, in particular prostate cancer.

US Patent:

20130315870, Nov 28, 2013

Filed:

Jun 29, 2011

Appl. No.:

13/807359

Inventors:

Shawn Edward Lupold - Ellicott City MD, US
Ping Wu - Baltimore MD, US
Ronald Rodriguez - Glenwood MD, US

Assignee:

THE JOHNS HOPKINS UNIVERSITY - Baltimore MD

International Classification:

C12N 15/86
C12N 15/10

US Classification:

424 932, 4353201, 506 9

Abstract:

The present invention relates to the field of viral gene therapy. More specifically, A the present invention provides compositions and methods for retargeting virus constructs. In one embodiment, the present invention provides an adenoviral construct comprising a nucleic acid encoding the peptide sequence MAE-X-PDP, wherein X is an antigen targeting peptide. In a more specific embodiment, an adenoviral construct comprises a nucleic acid sequence encoding the peptide sequence MAEWQPDTAHHWALTLPDP inserted into the HI-loop of adenovirus fiber protein. In yet another embodiment, the present invention provides a method for optimizing adenoviral infection of target cells comprising the steps of (a) generating a peptide-display adenovirus library, wherein the displayed peptide is a peptide that specifically binds an antigen expressed on the surface of a target cell, and wherein the displayed peptide is flanked by random peptide sequences; and (b) screening the peptide-display adenovirus library against the target cells.

US Patent:

20140017668, Jan 16, 2014

Filed:

Jun 30, 2011

Appl. No.:

13/807366

Inventors:

Shawn Edward Lupold - Ellicott City MD, US
Wasim Haider Chowdhury - Laurel MD, US
Ping Wu - Baltimore MD, US
Ronald Rodriguez - Glenwood MD, US

Assignee:

THE JOHNS HOPKINS UNIVERSITY - Baltimore MD

International Classification:

C12Q 1/68
C12N 15/86

US Classification:

435 5, 4353021

Abstract:

The present invention relates to the field of virology. More specifically, the present invention relates to the use of viral constructs to detect and quantify circulating tumor cells. In one embodiment, the present invention provides an adenovirus construct comprising (a) a cell type specific promoter that drives adenoviral replication; and (b) at least one reporter gene incorporated into the viral Major Late Transcriptional Unit. In another embodiment, an adenovirus construct comprises (a) prostate selective pro-basin promoter operably linked to the El gene; and (b) prostate specific antigen enhancer operably linked to the probasin promoter.